# OC-LEAD (Galleri in BRCA carriers at risk of ovarian cancer)

Source: https://onco.cc/trials/oc-lead/  
OnCo record `oc-lead` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A feasibility study of the Galleri blood test in people with BRCA gene changes who face a high risk of ovarian cancer.

## Summary

OC-LEAD (NCT07764744) is a non-randomised interventional study sponsored by Weill Medical College of Cornell University with M.D. Anderson Cancer Center. Its primary outcomes are the feasibility of Galleri testing in a surgical BRCA1/2 cohort and of annual testing in a cohort with serous tubal intraepithelial carcinoma.

The registry record, read on 29 October 2026, gives its status as not yet recruiting, with an estimated 70 participants, a planned start in October 2026 and primary completion expected in October 2039.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-29
- Also known as: OC-LEAD
- Registry id: NCT07764744
- Phase: not-applicable
- Setting: People with a BRCA1 or BRCA2 pathogenic variant at high risk of ovarian cancer, including a cohort with serous tubal intraepithelial carcinoma, given the Galleri test
- Sponsor: Weill Medical College of Cornell University with M.D. Anderson Cancer Center
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07764744: https://clinicaltrials.gov/study/NCT07764744

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)

---
JSON: https://onco.cc/api/v1/entities/oc-lead.json